Oppenheimer Maintains Outperform on Soleno Therapeutics, Lowers Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) but lowers the price target from $65 to $59.

May 13, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Soleno Therapeutics but reduces the price target from $65 to $59.
While the reduction in price target could suggest a tempered outlook, the maintenance of an Outperform rating indicates continued confidence in the company's prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the implications.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100